Enliven Therapeutics Q2 net loss widens on higher expenses
ELVN•Cash position and outlook
Enliven said its cash position rose to $895 million, which it expects to provide runway into 2030.
The company expects to initiate the ENABLE-2 Phase 3 trial for ELVN-001 in the second half of 2026. Additional Phase 3 trial design details are expected to be finalized after a planned FDA meeting in Q3 2026.
Q2 loss widens as expenses rise
Enliven Therapeutics' second-quarter net loss widened year over year as operating expenses increased.
The company reported a Q2 net loss of $32.49 million, compared with prior-year results, and income from operations of -$37.21 million. Loss per basic share was $0.49. Operating expenses were $37.21 million.
Clinical and regulatory progress
The company announced positive Phase 1 clinical data for ELVN-001 in chronic myeloid leukemia (CML), supporting further development.
Enliven said higher research and development expenses reflected advancement of the ELVN-001 clinical program. The company also said it reached alignment with the FDA on key Phase 3 trial design and received Fast Track designation.
